Health & Biotech CardieX wants to become Omron’s worst nightmare June 24, 2021 Special Report: It’s been a big few weeks for CardieX (ASX:CDX) as the health technology company restructured itself into two… Why this hidden gem in the Incannex product suite could be a global market winner June 24, 2021 Special Report: The company now has a targeted research pathway to clinical success, with strong proprietary protection as it moves… Check Up: From Moderna’s effective jabs to Patrys’ brain cancer breakthrough June 24, 2021 Here’s our fortnightly wrap of all the news driving ASX health stocks. The healthcare sector has returned 3.5 per cent… Actinogen Medical gets a further boost from supportive FDA advice, shares up 7-fold in 2021 June 23, 2021 Actinogen Medical (ASX:ACW) shares went even higher this morning after positive feedback in relation to a pre-Investigational New Drug (pre-IND)… Stock Insiders: SKN lands $20M equity facility deal, accelerates COVID-19 ‘Invisi Shield’ rollout June 23, 2021 Skin Elements is an ASX-listed company focused on designing and formulating natural, organic, health and wellness products for the global… NeuroScientific Biopharmaceuticals now has a research partner for its Phase I EmtinB trial June 23, 2021 Special Report: NeuroScientific Biopharmaceuticals (ASX:NSB) edged even closer to a planned Phase I clinical trial of EmtinBTM. Suda Pharma pops 44pc on cap raise; Acrux and other biotechs whet investor appetites June 22, 2021 Plenty of action on the biotech front today has provided ASX investors with some mouth-watering gains. Suda Pharma (ASX:SUD) led… ‘Massive’ opportunity in psychedelic-based therapy, expert says June 22, 2021 Psychedelic-based medicine presents a "massive" market opportunity, especially for companies that get in early, a British expert says. Dr Adrienne… Acrux shares gain after FDA approves its toenail fungus treatment June 22, 2021 After a tumultuous journey, biotech Acrux (ASX:ACR) will finally be able to sell its toenail fungus treatment in the USA.… NeuroScientific Biopharmaceuticals recruits Paradigm’s Paul Rennie as non-executive chairman June 22, 2021 Special Report: After overseeing Paradigm Biopharmaceuticals’ (ASX:PAR) rise to 14-bagger highs, Paul Rennie has joined NeuroScientific Biopharmaceuticals (ASX:NSB) as Non-executive… Next» « Previous